0001842952-21-000027.txt : 20211217
0001842952-21-000027.hdr.sgml : 20211217
20211217161834
ACCESSION NUMBER: 0001842952-21-000027
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211022
FILED AS OF DATE: 20211217
DATE AS OF CHANGE: 20211217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lehr Martin A.
CENTRAL INDEX KEY: 0001861989
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40654
FILM NUMBER: 211501811
MAIL ADDRESS:
STREET 1: 3675 MARKET STREET
STREET 2: SUITE 200
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Context Therapeutics Inc.
CENTRAL INDEX KEY: 0001842952
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472566423
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3675 MARKET STREET
STREET 2: SUITE 200
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
BUSINESS PHONE: 267-225-7416
MAIL ADDRESS:
STREET 1: 3675 MARKET STREET
STREET 2: SUITE 200
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
FORMER COMPANY:
FORMER CONFORMED NAME: Context Therapeutics LLC
DATE OF NAME CHANGE: 20210128
4/A
1
wf-form4a_163977590040895.xml
FORM 4/A
X0306
4/A
2021-10-22
2021-10-22
0
0001842952
Context Therapeutics Inc.
CNTX
0001861989
Lehr Martin A.
3675 MARKET STREET
SUITE 200
PHILADELPHIA
PA
19104
1
1
0
0
Chief Executive Officer
Common Stock
89583
D
Common Stock
2021-10-22
4
O
0
52680
7.14
A
0
I
Martin Lehr 2000 Trust
Common Stock
2021-10-22
4
C
0
210715
A
210715
I
Martin Lehr 2000 Trust
Common Stock
2021-10-22
4
C
0
586475
A
797190
I
Martin Lehr 2000 Trust
Common Stock
2021-10-22
4
P
0
10000
5
A
807190
I
Martin Lehr 2000 Trust
Warrant (right to buy)
7.14
2021-10-22
4
O
0
52680
0
A
2020-12-20
2030-12-20
Common Stock
52680.0
0
I
Martin Lehr 2000 Trust
Series A Preferred Stock
2021-10-22
4
C
0
210715
D
Common Stock
210715.0
7
I
Martin Lehr 2000 Trust
Series Seed Preferred Stock
2021-10-22
4
C
0
586475
D
Common Stock
586475.0
1
I
Martin Lehr 2000 Trust
Each share of Series A Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.
Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.
Fully vested.
The attached amends and restates the Form 4 filed on October 25, 2021 in its entirety
/s/ Alex Levit, Attorney-in-Fact
2021-12-17